U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830225) titled 'A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.' on Sept. 15.
Brief Summary: This is a phase II pilot study evaluating the use of circulating tumor DNA (ctDNA) to guide the optimal duration of standard of care immune checkpoint inhibitor (ICI) therapy in patients with unresectable and/or metastatic melanoma who have radiographic evidence of disease control and/or response to treatment.
Study Start Date: Sept. 03
Study Type: INTERVENTIONAL
Condition:
Melanoma (Skin Cancer)
Intervention:
OTHER: A Pilot Study of ctDNA-guided immune checkpoint inhibitor duration in patients w...